FDA Approves Fulyzaq 125 mg Delayed-Release Tablets for Relief of Diarrhea in Patients with HIV/AIDS on Anti-Retroviral Therapy

Salix Pharmaceuticals

today announced that the Food and Drug Administration has approved Fulyzaq (crofelemer) 125 mg delayed-release tablets for the symptomatic relief of non-infectious diarrhea in adult patients with human immunodeficiency virus (HIV)/ acquired immune deficiency syndrome (AIDS) on anti-retroviral therapy (ART). “The FDA approval of Fulyzaq is a significant step forward in addressing the unmet medical need of people with HIV/AIDS on ART who experience non-infectious diarrhea, which often can lead to reduced treatment compliance,” said Carolyn Logan, President and CEO of Salix. “Since the introduction of antiretroviral therapy, people with HIV are living longer and thus medication compliance and tolerability as well as quality